Multicentre, short-term therapeutic trial of disodium cromoglycate, with and without prednisone, in adults with asthma.
A total of 117 asthmatic patients were studied in a double-blind, cross-over trial with half-periods of three weeks in which disodium cromoglycate (D.S.C.G.) was compared with an inactive preparation. D.S.C.G. improved spirometric measurements, at a very high level of statistical significance, more than did placebo. The mean advantage of D.S.C.G. was less than 10% after three weeks. Symptomatic improvement by D.S.C.G. was small though significant; it was not correlated with spirometric improvement. A history of chronic cough was the only clinical characteristic associated with a better-than-average spirometric response to D.S.C.G.
D000328:Adult; D000605:Amino Alcohols; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003371:Cough / Q000503:physiopathology; D004205:Cromolyn Sodium / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage* / Q000627:therapeutic use; D013147:Spirometry; D013997:Time Factors; D014797:Vital Capacity
D000605:Amino Alcohols; D001993:Bronchodilator Agents; D004205:Cromolyn Sodium; D011241:Prednisone